These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25569705)

  • 1. A combination of 2D similarity search, pharmacophore, and molecular docking techniques for the identification of vascular endothelial growth factor receptor-2 inhibitors.
    Ai G; Tian C; Deng D; Fida G; Chen H; Ma Y; Ding L; Gu Y
    Anticancer Drugs; 2015 Apr; 26(4):399-409. PubMed ID: 25569705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An integrated virtual screening approach for VEGFR-2 inhibitors.
    Zhang Y; Yang S; Jiao Y; Liu H; Yuan H; Lu S; Ran T; Yao S; Ke Z; Xu J; Xiong X; Chen Y; Lu T
    J Chem Inf Model; 2013 Dec; 53(12):3163-77. PubMed ID: 24266594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel vascular endothelial growth factor receptor 2 inhibitors: a virtual screening approach.
    Zhang L; Wang X; Feng J; Jia Y; Xu F; Xu W
    Chem Biol Drug Des; 2012 Dec; 80(6):893-901. PubMed ID: 22913881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virtual screening and synthesis of new chemical scaffolds as VEGFR-2 kinase inhibitors.
    Elsayed MS; El-Araby ME; Serya RT; Abouzid KA
    Arzneimittelforschung; 2012 Dec; 62(12):554-60. PubMed ID: 23023518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico insights into the identification of potential novel angiogenic inhibitors against human VEGFR-2: a new SAR-based hierarchical clustering approach.
    Konidala KK; Bommu UD; Pabbaraju N
    J Recept Signal Transduct Res; 2018 Aug; 38(4):372-383. PubMed ID: 30396316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based identification of potent VEGFR-2 inhibitors from in vivo metabolites of a herbal ingredient.
    Dash R; Junaid M; Mitra S; Arifuzzaman M; Hosen SMZ
    J Mol Model; 2019 Mar; 25(4):98. PubMed ID: 30904971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
    Rathi E; Kumar A; Kini SG
    J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in structure-based drug design and virtual screening of VEGFR tyrosine kinase inhibitors.
    Hoi PM; Li S; Vong CT; Tseng HH; Kwan YW; Lee SM
    Methods; 2015 Jan; 71():85-91. PubMed ID: 25239735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase.
    Rizvi SU; Siddiqui HL; Nisar M; Khan N; Khan I
    Bioorg Med Chem Lett; 2012 Jan; 22(2):942-4. PubMed ID: 22200597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
    Bhojwani HR; Joshi UJ
    Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a highly-potent anti-angiogenic VEGF8-109 heterodimer by directed blocking of its VEGFR-2 binding site.
    Ghavamipour F; Shahangian SS; Sajedi RH; Arab SS; Mansouri K; Aghamaali MR
    FEBS J; 2014 Oct; 281(19):4479-94. PubMed ID: 25132001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of new 4-alkoxyquinazoline-based derivatives as potent VEGFR2 inhibitors.
    Yin Y; Sha S; Wang YT; Wu X; Wang SF; Qiao F; Lv PC; Zhu HL
    Chem Biol Drug Des; 2015 Nov; 86(5):1323-9. PubMed ID: 26032487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving VEGFR-2 docking-based screening by pharmacophore postfiltering and similarity search postprocessing.
    Planesas JM; Claramunt RM; Teixidó J; Borrell JI; Pérez-Nueno VI
    J Chem Inf Model; 2011 Apr; 51(4):777-87. PubMed ID: 21417262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-Based Virtual Screening for the Identification of High Affinity Compounds as Potent VEGFR2 Inhibitors for the Treatment of Renal Cell Carcinoma.
    Sharma K; Patidar K; Ali MA; Patil P; Goud H; Hussain T; Nayarisseri A; Singh SK
    Curr Top Med Chem; 2018; 18(25):2174-2185. PubMed ID: 30499413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacophore based 3D-QSAR modeling and free energy analysis of VEGFR-2 inhibitors.
    Rajagopalan M; Balasubramanian S; Ramaswamy A; Mathur PP
    J Enzyme Inhib Med Chem; 2013 Dec; 28(6):1236-46. PubMed ID: 23061928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective flexibility of side-chain residues improves VEGFR-2 docking score using AutoDock Vina.
    Abreu RM; Froufe HJ; Queiroz MJ; Ferreira IC
    Chem Biol Drug Des; 2012 Apr; 79(4):530-4. PubMed ID: 22188672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents.
    Aziz MA; Serya RA; Lasheen DS; Abdel-Aziz AK; Esmat A; Mansour AM; Singab AN; Abouzid KA
    Sci Rep; 2016 Apr; 6():24460. PubMed ID: 27080011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
    Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
    Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.
    Lee K; Jeong KW; Lee Y; Song JY; Kim MS; Lee GS; Kim Y
    Eur J Med Chem; 2010 Nov; 45(11):5420-7. PubMed ID: 20869793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis and Evaluation of 5-pyridin-4-yl-2-thioxo-[1,3,4]oxadiazol-3-yl Derivatives as Anti-angiogenic Agents Targeting VEGFR-2.
    Bhanushali U; Kalekar-Joshi S; Kulkarni-Munshi R; Yellanki S; Medishetty R; Kulkarni P; Chelakara RS
    Anticancer Agents Med Chem; 2017; 17(1):67-74. PubMed ID: 27141880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.